Open AccessClinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing
Author(s) -
Gregory Mathez,
Valeria Cagno
Publication year - 2021
Publication title -
antiviral chemistry and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.919
H-Index - 51
eISSN - 2040-2066
pISSN - 0956-3202
DOI - 10.1177/20402066211061063
Subject(s) - virology , coronavirus , virus , viral replication , biology , respiratory system , middle east respiratory syndrome coronavirus , immunology , titer , medicine , covid-19 , disease , infectious disease (medical specialty) , anatomy
Severe acute respiratory syndrome coronavirus 2 is an RNA virus currently causing a pandemic. Due to errors during replication, mutations can occur and result in cell adaptation by the virus or in the rise of new variants. This can change the attachment receptors' usage, result in different morphology of plaques, and can affect as well antiviral development. Indeed, a molecule can be active on laboratory strains but not necessarily on circulating strains or be effective only against some viral variants. Experiments with clinical samples with limited cell adaptation should be performed to confirm the efficiency of drugs of interest. In this protocol, we present a method to culture severe acute respiratory syndrome coronavirus 2 from nasopharyngeal swabs, obtain a high viral titer while limiting cell adaptation, and assess antiviral efficiency.